Lifastuzumab vedotine (SLC34A2) - Research Grid Biosimilar
Gecertificeerd

Lifastuzumab vedotine (SLC34A2) - Research Grid Biosimilar

Catalog #: 10-628
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer) .

Immunogen

Humanized / SLC34A2 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Cancer

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG1-kappa

NCBI Organism

Homo sapiens

Other Product Names

DNIB0600A (conjugate), MNIB2126A (non conjugate)

Beschrijving

Lifastuzumab vedotine (SLC34A2) - Research Grid Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamLifastuzumab vedotine (SLC34A2) - Research Grid Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-628